跳至主要内容
临床试验/ACTRN12622000309785
ACTRN12622000309785撤回未知

Therapies to prevent progression of COVID-19, including Quercetin, Zinc, high dose Vitamin D with or without Intravenous Vitamin C, a multi-centre, international, randomized trial: The International ALLIANCE Study - Stage 2

AProf Dr Karin Ried0 个研究点目标入组 200 人开始时间: 2022年2月18日最近更新:
适应症

试验速览

阶段
未知
状态
撤回
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Diagnosis of active COVID-19
  • Provision of informed consent in writing, can be electronic

排除标准

  • 1) Known G6PD deficiency
  • 2) Contra-indication to quercetin or Vitamin C: allergy to study interventions, epilepsy, serious hearing or visual problems, history of severe depression, calcium oxalate stones, advanced liver disease, pregnancy or lactating
  • 3) Already receiving quercetin, or more than 3 grams Vitamin C daily or an experimental antiviral
  • 4) History of fever (e.g. night sweats, chills) and/or acute respiratory infection (e.g. cough, shortness of breath, sore throat) of more than 7 days’ duration. Note, if study numbers not quickly reached, the investigators may decide to include those with symptoms of longer than 7 days
  • 5) Calculated creatinine clearance of less than 30 mL/minute

研究者

发起方
AProf Dr Karin Ried

相似试验